Inhibrx Biosciences, Inc. (INBX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inhibrx Biosciences, Inc. (INBX) has a cash flow conversion efficiency ratio of -3.769x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.12 Million) by net assets ($7.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See INBX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Inhibrx Biosciences, Inc. - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Inhibrx Biosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inhibrx Biosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inhibrx Biosciences, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Svitzer Group A/S
CO:SVITZR
|
N/A |
|
CLARIVATE PLC
NYSE:CLVT
|
0.028x |
|
Dalata Hotel Group Plc
IR:DHG
|
0.022x |
|
American Axle & Manufacturing
NYSE:AXL
|
0.188x |
|
Science Environmental Protection Co. Ltd. A
SHG:688480
|
N/A |
|
Milkyway Chemical Supply Chain Service Co Ltd
SHG:603713
|
-0.059x |
|
Labrador Iron Ore Royalty Corp
TO:LIF
|
0.051x |
|
IMMUNOCORE HLDGS ADS/1
F:6YG
|
-0.086x |
Annual Cash Flow Conversion Efficiency for Inhibrx Biosciences, Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Inhibrx Biosciences, Inc. from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Inhibrx Biosciences, Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.99 Million | $-129.79 Million | -16.238x | -1015.79% |
| 2024-12-31 | $133.58 Million | $-194.41 Million | -1.455x | +67.25% |
| 2023-12-31 | $43.50 Million | $-193.31 Million | -4.444x | -123.75% |
| 2022-12-31 | $58.06 Million | $-115.30 Million | -1.986x | -29.52% |
| 2021-12-31 | $52.38 Million | $-80.32 Million | -1.533x | -141.26% |
| 2020-12-31 | $75.47 Million | $-47.97 Million | -0.636x | -285.38% |
| 2019-12-31 | $-93.57 Million | $-32.08 Million | 0.343x | -14.42% |
| 2018-12-31 | $-57.64 Million | $-23.09 Million | 0.401x | -52.10% |
| 2017-12-31 | $-22.42 Million | $-18.75 Million | 0.836x | +105.72% |
| 2016-12-31 | $1.24 Million | $-18.11 Million | -14.615x | -- |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-bas… Read more